Stocks Health care ABT
NYSE · Health careAbbott Laboratories (ABT)
Abbott Laboratories brought in $48.2B of revenue over the twelve months to September 30, 2026, up 10.0% from a year earlier. Net income was $4.7B, a net margin of 9.7%. Operating cash flow minus capital spending left $7.4B of free cash flow in fiscal 2025. At September 30, 2026 it held $4.1B in cash against $31.2B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Abbott Laboratories
- Net worth
- Abbott Laboratories has a market value (market cap) of $191.1B at the latest share price, and shareholders' equity of $51B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $44.3B (+5.7% year on year), with net income of $6.5B. Over the 12 months to September 30, 2026: revenue $48.2B, net income $4.7B.
- Cash flow
- In fiscal 2025 operations brought in $9.6B of cash; after $2.2B of capital spending, free cash flow was $7.4B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Abbott Laboratories's next report is expected around January 21, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- Abbott Laboratories declared dividends of $2.40 per share in fiscal 2025, a yield of 2.17% at the current price.
What Abbott Laboratories does
Abbott Laboratories develops, manufactures, and sells healthcare products. Its product line includes medical diagnostic equipment, cardiovascular and neuromodulation devices, adult and pediatric nutritional products, and branded generic pharmaceuticals sold to hospitals, clinics, pharmacies, and consumers. Its shares trade on NYSE under the ticker ABT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $44.3B | $6.5B | $3.72 | $7.4B |
| 2024 | $42B | $13.4B | $7.64 | $6.4B |
| 2023 | $40.1B | $5.7B | $3.26 | $5.1B |
| 2022 | $43.7B | $6.9B | $3.91 | $7.8B |
| 2021 | $43.1B | $7.1B | $3.94 | $8.6B |
| 2020 | $34.6B | $4.5B | $2.50 | $5.7B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ABT ranks in Health care
Dividends
Abbott Laboratories declared $2.40 per share in fiscal 2025. At the current price that is a yield of 2.17%. It paid out $4.1B in cash dividends, 63% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $2.40 | $4.1B | 63% |
| 2024 | $2.24 | $3.8B | 29% |
| 2023 | $2.08 | $3.6B | 62% |
| 2022 | $1.92 | $3.3B | 48% |
| 2021 | n/a | $3.2B | 45% |
| 2020 | n/a | $2.6B | 57% |
Latest SEC filings
What Abbott Laboratories has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 14% to $13B versus the same quarter last year; diluted EPS $0.53 versus $0.94.
- October 21, 2026Other event 8-K
- October 21, 2026
- August 20, 2026
- July 28, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 13% to $12.6B versus the same quarter last year; diluted EPS $0.53 versus $1.01.
- July 16, 2026
- June 18, 2026
- May 27, 2026
- April 29, 2026Passive stake (5% or more) SCHEDULE 13G
- April 29, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 7.8% to $11.2B versus the same quarter last year; diluted EPS $0.61 versus $0.76.
What is ABT worth? A DCF from its reported cash flow
Insider trades
What the people running Abbott Laboratories did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $46.6M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 5, 2026 | Moreland Mary KEXECUTIVE VICE PRESIDENT | Sold | 3,500 | $406K |
| September 23, 2026 | Conroy Kevin TDirector | Shares withheld for tax | 52,507 | $5.5M |
| September 2, 2026 | Mccoy John A. Jr.VICE PRESIDENT AND CONTROLLER | Sold | 27 | $3K |
| September 1, 2026 | Mccoy John A. Jr.VICE PRESIDENT AND CONTROLLER | Shares withheld for tax | 52 | $5.7K |
| September 1, 2026 | Boudreau Philip PEVP AND CFO | Shares withheld for tax | 388 | $42.8K |
| August 25, 2026 | Ford Robert BCHAIRMAN AND CEO, Director | Exercised options | 151,869 | $6.7M |
| August 25, 2026 | Ford Robert BCHAIRMAN AND CEO, Director | Exercised options | 246,963 | $14.8M |
| August 25, 2026 | Ford Robert BCHAIRMAN AND CEO, Director | Sold | 218,535 | $25.3M |
Who owns ABT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 7.5% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 2,965 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 152,563,476 | +6,876,018 |
| Vanguard Capital Management LLC | 113,750,994 | +801,061 |
| State Street Corp | 80,926,234 | +1,350,766 |
| Charles Schwab Investment Management Inc | 59,674,507 | +14,174,452 |
| Vanguard Portfolio Management LLC | 49,017,866 | +1,072,975 |
| Geode Capital Management, LLC | 39,219,337 | +70,542 |
| Capital Research Global Investors | 36,908,990 | -12,866,372 |
| Capital International Investors | 34,654,113 | -2,844,114 |
| Morgan Stanley | 26,611,315 | -3,490,281 |
| Norges Bank | 23,354,911 | new |
| Franklin Resources Inc | 18,806,911 | -1,215,994 |
| Northern Trust Corp | 18,273,301 | -1,121,673 |
| Bank of America Corp | 17,672,543 | -1,607,065 |
| Goldman Sachs Group Inc | 16,760,070 | +2,254,869 |
| Deutsche Bank AG\ | 16,706,669 | +2,614,965 |
| Jpmorgan Chase & Co | 15,095,898 | -11,671,201 |
| Wells Fargo & Company | 15,177,317 | -732,024 |
| State Farm Mutual Automobile Insurance Co | 13,587,118 | 0 |
| Massachusetts Financial Services Co | 13,359,956 | -2,139,914 |
| Fmr LLC | 13,423,080 | +2,577,765 |
Insiders
23 insiders reported holding 8,251,596 shares in total, about $911.5M at the last price.
| Holder | Shares |
|---|---|
| Starks Daniel JDirector | 6,751,103 |
| Ford Robert BCHAIRMAN AND CEO, Director | 522,664216,203 held indirectly |
| Salvadori Daniel Gesua SiveEVP AND GROUP PRESIDENT | 146,377 |
| Moreland Mary KEXECUTIVE VICE PRESIDENT | 117,95017,159 held indirectly |
| Earnhardt Lisa DEVP AND GROUP PRESIDENT | 90,407 |
| Conroy Kevin TDirector | 81,230 |
| Scoggins Christopher JEXECUTIVE VICE PRESIDENT | 77,126 |
| Boudreau Philip PEVP AND CFO | 72,9842,200 held indirectly |
| Morrone Louis H.EXECUTIVE VICE PRESIDENT | 70,724 |
| Orville Jacob ASenior Vice President | 50,493 |
Questions about ABT
What does Abbott Laboratories do?
Abbott Laboratories develops, manufactures, and sells healthcare products. Its product line includes medical diagnostic equipment, cardiovascular and neuromodulation devices, adult and pediatric nutritional products, and branded generic pharmaceuticals sold to hospitals, clinics, pharmacies, and consumers. Its shares trade on NYSE under the ticker ABT.
What is Abbott Laboratories's net worth?
Abbott Laboratories has a market value (market cap) of $191.1B at the latest share price, and shareholders' equity of $51B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Abbott Laboratories profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $4.7B on revenue of $48.2B, a net margin of 9.7%.
How much revenue does Abbott Laboratories make?
Over the twelve months to September 30, 2026 Abbott Laboratories reported revenue of $48.2B. That is 10.0% more than a year earlier.
When did Abbott Laboratories last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 6, 2026.
When is Abbott Laboratories's next earnings report?
Abbott Laboratories's next report is expected around January 21, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Does Abbott Laboratories pay a dividend?
Yes. Abbott Laboratories declared dividends of $2.40 per share in fiscal 2025, a yield of 2.17% at the current price.
Similar companies
Compare ABT with
Follow ABT
Get an email when Abbott Laboratories files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Abbott Laboratories tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.